Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation
Novo Nordisk A/S Bagsværd, Denmark, 31 July 2026 – Novo Nordisk today announced headline results from the ZEUS cardiovascular…
Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation
Novo Nordisk A/S Bagsværd, Denmark, 31 July 2026 – Novo Nordisk today announced headline results from the ZEUS cardiovascular…
Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke
Novo Nordisk A/S The Novo Nordisk study POSEIDON – including 18,904 patients across 18 countries – showed that…
Novo Nordisk global observational study reveals 2 in 5
The Novo Nordisk study POSEIDON – including 18,904 patients across 18 countries – showed that cardiovascular (CV) inflammation…
Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke
Novo Nordisk A/S The Novo Nordisk study POSEIDON – including 18,904 patients across 18 countries – showed that…